包涵体：现状与展望。

Inclusion Bodies: Status Quo and Perspectives.

机构信息

Research Division Integrated Bioprocess Development, TU Wien Institute of Chemical, Environmental, and Bioscience Engineering, Vienna, Austria.

出版信息

Methods Mol Biol. 2023;2617:1-13. doi: 10.1007/978-1-0716-2930-7_1.

DOI:10.1007/978-1-0716-2930-7_1

PMID:36656513

Abstract

Multiple E. coli cultivations, producing recombinant proteins, lead to the formation of inclusion bodies (IBs). IBs historically were considered as nondesired by-products, due to their time- and cost-intensive purification. Nowadays, many obstacles in IB processing can be overcome. As a consequence, several industrial processes with E. coli favor IB formation over soluble production options due to the high space time yields obtained. Within this chapter, we discuss the state-of-the art biopharmaceutical IB process, review its challenges, highlight the recent developments and perspectives, and also propose alternative solutions, compared to the state-of-the art processing.

摘要

多次大肠杆菌培养生产重组蛋白会导致包涵体（IB）的形成。由于包涵体的纯化既耗时又昂贵，因此历史上它们被认为是不受欢迎的副产物。如今，许多包涵体处理方面的障碍都已被克服。因此，由于获得的高时空产率，许多采用大肠杆菌的工业生产过程更倾向于形成包涵体，而不是选择可溶表达产物。在本章中，我们讨论了最先进的生物制药包涵体工艺，回顾了其面临的挑战，强调了最近的发展和前景，并与最先进的工艺相比提出了替代解决方案。